Meyer-Rienecker H J, Günther J, Gundlach H J, Schröter P, Hitzchke B
Psychiatr Neurol Med Psychol (Leipz). 1975 Dec;27(12):725-36.
The induction of immunological tolerance with, and for, the caused organotypical antigen is a conception for a specific therapy for neuroimmunological diseases with at least a partial autoallergic pathogenesis. Appropriate to a set step-by-step programme for the development of antigen-specific therapy preventive tolerance experiments were carried out at the model of experimental allergic encephalomyelitis (EAEM) with allogenic myelin basic protein (BP) prepared from rabbits. The result is: 100 ug BP given intravenously simultaneously with 100 ug BP in incomplete Freud's adjuvant given intracutanously twice a week and 40 mg Cyclophosphamid given daily during the minor clinical incidence rate and no signs of EAEM pathomorphologically. A longlasting tolerance for the BP could be obtained as a test proved after 100 days. Hints are given for further potential therapeutic treatments, such as the use of antigen bound chemically to the immunosuppressive drug or the use of chemically modified BP for the induction of a specific tolerance.
针对引发疾病的器官特异性抗原诱导免疫耐受,是针对至少具有部分自身免疫发病机制的神经免疫疾病进行特异性治疗的一种理念。按照用于开发抗原特异性治疗的循序渐进程序,在实验性变应性脑脊髓炎(EAEM)模型中,使用从兔子制备的同种异体髓鞘碱性蛋白(BP)进行了预防性耐受实验。结果是:静脉注射100μg BP,同时每周两次皮内注射100μg BP于不完全弗氏佐剂中,并在轻微临床发病率期间每日给予40mg环磷酰胺,病理形态学上无EAEM迹象。100天后的一项测试证明,可以获得对BP的持久耐受性。文中还给出了进一步潜在治疗方法的提示,例如使用与免疫抑制药物化学结合的抗原,或使用化学修饰的BP来诱导特异性耐受。